Whalesbook
Currency Tailwinds Boost Exporters
India's pharmaceutical companies are set to see a significant earnings boost in fiscal year 2027 due to the rupee's continued depreciation, particularly those with substantial international sales. Elara Securities forecasts that a weaker rupee could lift reported revenues by up to 5% and EBITDA by as much as 15% for 18 major drugmakers. This benefit stems from the sector's heavy reliance on overseas markets, with many firms earning the majority of their income abroad. For instance, Aurobindo Pharma and Gland Pharma earn over 90% of their revenue internationally, and another eleven companies, including Zydus Lifesciences, generate more than 70% from abroad. The rupee has weakened against major currencies over recent months. If current exchange rates persist, it could be 6-15% lower in FY27 than in FY26, partly driven by escalating geopolitical tensions in the Middle East that have pushed Brent crude prices up to nearly $120 a barrel.
Who Benefits Most and Who Faces Pressure
Elara Securities noted that "given their geographic revenue mix and the extent of INR depreciation against respective currencies, nearly all companies in our pharma universe stand to benefit." They estimate that foreign currencies remaining about 5.8% stronger against the rupee could add an incremental 1-5% to revenues for most firms. Biocon, Granules India, Aurobindo Pharma, and Gland Pharma are expected to see the strongest positive impact due to their extensive global operations. In contrast, companies focused primarily on the domestic Indian market, such as Eris Lifesciences and Mankind Pharma, may face pressure from higher import costs and increased overseas expenses.
Risks Beyond Currency
However, these currency gains are not without risks. The surge in crude oil prices, linked to Middle East tensions, not only impacts the rupee but also raises the cost of petrochemical derivatives used in manufacturing drug ingredients (APIs). This could erode some of the margin gains from a weaker rupee. For companies like Sun Pharma with significant exposure to the US market, continued pricing pressures and increased scrutiny from the U.S. Food and Drug Administration remain key concerns, irrespective of currency movements. Furthermore, while export-heavy firms are prime currency beneficiaries, they are also exposed to potential global economic slowdowns or unexpected regulatory changes in key overseas markets.
Valuation and Outlook
From an investor's perspective, export-oriented companies like Aurobindo Pharma (P/E around 18x) and Granules India (15x) appear attractively priced relative to their potential currency-driven profit uplift. This contrasts with higher-valued peers like Biocon (40x P/E) or Eris Lifesciences (35x P/E), which may be priced for different growth drivers. Sun Pharma (25x P/E) and Dr. Reddy's Laboratories (22x P/E) offer a balanced profile with strong domestic and export presence. Analysts expect currency advantages to remain a significant support for Indian pharma exporters through FY27. While brokerages are raising price targets, management at firms like Granules India and Biocon suggest they are cautiously monitoring input costs and global demand. The sector's sustained growth will depend on strategic diversification, innovation, and careful risk management in an unpredictable global economy.